{
    "clinical_study": {
        "@rank": "163316", 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and efficacy of propanolol in the early\n      treatment of cocaine dependence."
        }, 
        "brief_title": "Propranolol for Treatment of Cocaine Addiction - 2", 
        "completion_date": {
            "#text": "January 2002", 
            "@type": "Actual"
        }, 
        "condition": "Cocaine-Related Disorders", 
        "condition_browse": {
            "mesh_term": "Cocaine-Related Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Please contact site for information."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "49 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": "0", 
        "firstreceived_date": "September 20, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000197", 
            "org_study_id": "NIDA-00238-2", 
            "secondary_id": "K20DA000238"
        }, 
        "intervention": {
            "intervention_name": "Propranolol", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Propranolol"
        }, 
        "is_fda_regulated": "Yes", 
        "lastchanged_date": "February 3, 2010", 
        "location": {
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19104 6178"
                }, 
                "name": "University of Pennsylvania"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Propranolol for Treatment of Cocaine Addiction", 
        "overall_official": {
            "affiliation": "University of Pennsylvania", 
            "last_name": "Kyle Kampman, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2002", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Side effects"
            }, 
            {
                "measure": "Cocaine use"
            }, 
            {
                "measure": "Cocaine withdrawal"
            }, 
            {
                "measure": "Cocaine craving"
            }, 
            {
                "measure": "Mood and anxiety"
            }, 
            {
                "measure": "Clinical improvement"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000197"
        }, 
        "responsible_party": {
            "name_title": "Kyle Kampman", 
            "organization": "University of Pennsylvania"
        }, 
        "source": "National Institute on Drug Abuse (NIDA)", 
        "sponsors": {
            "collaborator": {
                "agency": "University of Pennsylvania", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Institute on Drug Abuse (NIDA)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "January 1987", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2010"
    }, 
    "geocoordinates": {
        "University of Pennsylvania": "39.952 -75.164"
    }
}